Posted on 1/3/19
Takeda Announces Multiple Cell Therapy Collaborations
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) today announced new research collaborations in immuno-oncology (I-O), an area of key strategic focus for . . .
Posted on 1/3/19
Neon Therapeutics Provides Business Update
CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today provided a business update and . . .
Posted on 1/2/19
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board . . .
Posted on 1/2/19
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted six newly-hired . . .
Posted on 1/2/19
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced . . .
Posted on 1/2/19
Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron
CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases and Aldevron, the leading producer . . .
Posted on 1/2/19
Catabasis Pharmaceuticals Announces Reverse Stock Split
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it will effect a one-for-ten reverse stock split of its common stock that . . .
Posted on 1/2/19
EnClear Spins out of QurAlis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--EnClear Therapies, a medical device company focused on developing therapeutic systems that continuously clear toxic proteins from cerebrospinal fluids (CSF) for the treatment of . . .
Posted on 1/2/19
Ocular Therapeutix Announces Completion of Debt Refinancing
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the . . .
Posted on 1/1/19
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Dec. 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, granted equity awards on December . . .
Posted on 12/30/18
Peak Physical Therapy & Sports Performance Opens New Pediatric Program at Norwell Clinic
Physical Therapy & Sports Performance, a South Shore practice specializing in unique programs that provide comprehensive treatment in orthopedic, spine and sports medicine specialties, is pleased . . .
Posted on 12/21/18
Rubius Therapeutics Secures $75 Million Loan Facility
CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, today . . .
Posted on 12/21/18
AVROBIO Added to NASDAQ Biotechnology Index
CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO), a Phase 2 clinical-stage gene therapy company, today announced that the Company has been . . .
Posted on 12/21/18
Surface Oncology Added to the NASDAQ Biotechnology Index
CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today . . .
Posted on 12/21/18
Proteostasis Therapeutics Provides Clinical Enrollment Update
Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases . . .
Posted on 12/21/18
Unum Therapeutics Added to NASDAQ Biotechnology Index
CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular immunotherapies, today . . .
Posted on 12/20/18
CHI Selected as Harvard Business School Association of Boston’s Community Action Partner
Boston, MA, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Centering Healthcare Institute is partnering with the Harvard Business School Association of Boston in a pro bono consulting . . .
Posted on 12/20/18
Alcyone Lifesciences Announces Broad Strategic Collaboration with Roche in the Field of Intrathecal Therapies
Alcyone Lifesciences, Inc., a leader in breakthrough technologies to treat complex neurological and oncological conditions through the company's proprietary advanced precision delivery platform, announced that it . . .
Posted on 12/20/18
Gilead And Agenus Enter into Collaboration
Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and . . .
Posted on 12/20/18
Heritage Portfolio Company EPTAM Announces Add-On Acquisition of Relius Medical
New Heritage Capital is pleased to announce that its portfolio company EPTAM has acquired substantially all of the assets of Relius Medical, a Colorado Springs
Posted on 12/20/18
Federal Street Acquisition Corp. Amends Terms of Merger Agreement With Agiliti Health
BOSTON & MINNEAPOLIS--(BUSINESS WIRE)--Federal Street Acquisition Corp. (NASDAQ:FSACU, FSAC, FSACW), a special-purpose acquisition company sponsored by an affiliate of Thomas H. Lee Partners, L.P. , and . . .
Posted on 12/20/18
Relay Therapeutics Secures $400 Million in Series C Financing
Relay Therapeutics, a new breed of company at the intersection of computation and biotechnology, today announced the successful completion of a $400 million Series C financing.
Posted on 12/20/18
Verastem Oncology Added to the NASDAQ Biotechnology Index
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of . . .
Posted on 12/20/18
Dicerna to Join NASDAQ Biotechnology Index
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will be added to the . . .
Posted on 12/20/18
TPG Capital Backs BVI to Acquire PhysIOL Group SA
BVI (Beaver-Visitec International), a leading developer, manufacturer, and marketer of specialized surgical devices and custom procedure packs for the ophthalmic marketplace

